In a proof-of-concept clinical trial, Poolbeg Pharma will look into the potential of microencapsulation and nanoencapsulation oral delivery technologies. Poolbeg Pharma has acquired a licence from a sister company of
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced positive initial data analysis for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address
Poolbeg Pharma received initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet
Poolbeg Pharma has identified new potential drug candidates for respiratory syncytial virus (RSV) infections. The identification of potential RSV treatments has emerged from the company’s artificial intelligence (AI) programme alongside
Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus artificial intelligence Programme with OneThree
The big successes of his recent career are not what motivate Cathal Friel. The executive chair and co-founder of Open Orphan and Poolbeg Pharma says his drive goes back to
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced that it has acquired an exclusive licence from InsuCaps Limited, a sister company of AnaBio Technologies, to use
Poolbeg Pharma plc (LON:POLB’), a leading infectious disease focused biopharmaceutical company, has announced that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
